Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777775 | 0.91 | ADORA3 (0.39) | CDK1CCNB1ADORA3ADORA2AADORA1 | |
| SCHEMBL12373558 | 0.89 | ADORA2A (0.35) | CDK1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL12375030 | 0.88 | ADORA2A (0.34) | ADORA3ADORA2A | |
| SCHEMBL13741689 | 0.81 | ADORA2A (0.32) | ADORA3ADORA2A | |
| SCHEMBL3478694 | 0.81 | ADORA3 (0.37) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10146196 | 0.80 | ADORA3 (0.36) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL14393325 | 0.79 | SARS1 (0.40) | ADORA3ADORA2AADORA1 | |
| SCHEMBL12374009 | 0.79 | SARS1 (0.40) | ADORA3ADORA2AADORA1 | |
| SCHEMBL13777738 | 0.76 | ADORA3 (0.36) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10146742 | 0.76 | ADORA3 (0.36) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | CDK1 1224/4885CCNB1 2507/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.